BioSpect
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

Biocon appoints Susheel Umesh as CCO, Emerging Markets

02 March 2021 | News

Umesh has over 30 years of experience in the pharmaceuticals industry, having worked in India, France and Sub-Saharan Africa for leading global pharma companies.



Biocon Ltd announced that Susheel Umesh has joined Biocon Biologics as the Chief Commercial Officer - Emerging Markets (CCO-EMs) wef March 1, 2021. He will drive the company's business in the Emerging Markets (EMs) and will also be responsible for the Branded Formulations business.

Umesh has over 30 years of experience in the pharmaceuticals industry, having worked in India, France and Sub-Saharan Africa for leading global pharma companies. He has managed global brands as well as led different functions in India and overseas in sales & marketing, business development and operations excellence. Most recently, he led the domestic formulations of an Indian biotech company as its Chief Executive Officer.

With this appointment, Biocon Biologics will move its commercial operations from Singapore to its headquarters in Bengaluru.

Kiran Mazumdar-Shaw, Executive Chairperson, Biocon Biologics, said: "We are very happy to welcome Susheel Umesh to Biocon Biologics. As Chief Commercial Officer, Susheel will be responsible for driving the company's growth strategy in Emerging Markets on a platform of affordable access."

Dr Arun Chandavarkar, Managing Director, Biocon Biologics said, "We are extremely delighted to have Susheel Umesh lead our Commercial Operations for the Emerging Markets. Susheel has deep expertise in diverse therapy areas, including diabetes, oncology, cardiology and transplantation, and has a proven track record of delivering robust business growth."

Umesh said, "I am extremely proud to join Biocon Biologics, at this juncture where it has established a strong biosimilars business in global markets in collaboration with its partners. I believe the company is well-positioned to impact millions of patients globally, capitalising on its strengths in science and global scale manufacturing expertise."